Credit Suisse’s AC Immune ACIU Stock Holding History

Credit Suisse’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-15,768	Closed	-$80K	–	4069
2019 Q1	$80K	Buy	+15,768	New	+$100K	﹤0.01%	3870

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Credit Suisse's ACIU Position: Q2 2019 in Review

Credit Suisse sold out of AC Immune (ACIU) in Q2 2019, closing a stake of 15,768 shares — an estimated $80K sold.

Credit Suisse first reported a position in ACIU in Q1 2019 and held it in 1 quarter. The position peaked at $80K in Q1 2019. 40 funds tracked by Wall St. Rank hold ACIU as of Q2 2019.

Credit Suisse reported no remaining AC Immune position as of Q2 2019 after selling out during the quarter.
Credit Suisse sold 15,768 AC Immune shares in Q2 2019, an estimated $80K.
Credit Suisse first reported a position in AC Immune in Q1 2019 and held it in 1 quarter.
Credit Suisse's AC Immune position peaked at $80K in Q1 2019.
40 funds tracked by Wall St. Rank held AC Immune as of Q2 2019.

Based on Credit Suisse's 13F filing for Q2 2019, filed 14 Aug 2019.